Benevolent Platform Precision Medicine
Molecular Design - Expertise in structure-based design,
virtual screening and machine learning
We combine deep expertise in drug discovery with innovative techniques in structure-based design, virtual
screening and machine learning.
Highly experienced drug discovery team with a proven track record of taking nascent programme ideas and
delivering drugs to the clinic.
Chemoinformatic and Al tools impacting all stages of a drug programme from target selection through to
candidate selection.
Empowering chemists to design better drugs in fewer cycles - candidate drugs delivered in as little as 2 years
from programme inception compared to 3-5 year industry standard
Druggability scoring to
prioritise targets
Target ID
Binding site comparison to
identify Hit matter and
evaluate selectivity
Proprietary pharmacophore |
building methodology
ML models of activity and
ADMET endpoints
Hit Identification
Hit Expansion
Binding site detection to
identify differentiating
chemistry opportunities
Customisable virtual
screening pipeline now on
>10 billion compound scale
Confidential
Lead Optimisation
Candidate Seeking
Protein-Ligand interaction
mining to surface
protein-centric bioisosteres
Programme
visualisation
Benevolent 30View entire presentation